Long-term results of a phase 1/1b study of ibrutinib plus umbralisib for relapsed/refractory chronic lymphocytic leukemia.

COI Statement

Christine E. Ryan has received honoraria from Research to Practice, Curio Science, and AstraZeneca and has received institutional research funding from Genentech. Hari Miskin is an employee of TG Therapeutics. Peter Sportelli is an employee of TG Therapeutics. Jennifer R. Brown has served as a consultant for Abbvie, Acerta/Astra‐Zeneca, Alloplex Biotherapeutics, BeiGene, Bristol‐Myers Squibb, Galapagos NV, Genentech/Roche, Grifols Worldwide Operations, InnoCare Pharma Inc., iOnctura, Kite Pharma, Loxo/Lilly, Merck, Numab Therapeutics, Pfizer, Pharmacyclics; received research funding from BeiGene, Gilead, iOnctura, Loxo/Lilly, MEI Pharma, TG Therapeutics; and serves on the Data Safety Monitoring Board for Grifols Therapeutics. Matthew S. Davids has received consulting fees from AbbVie, Adaptive Biotechnologies, Ascentage Pharma, AstraZeneca, BeiGene, Bristol Myers Squibb, Genentech, Genmab, Janssen, Merck, MEI Pharma, Mingsight Pharmaceuticals, Nuvalent, Secura Bio, Takeda, and TG Therapeutics; has received institutional research funding from Ascentage Pharma, MEI Pharma, Novartis, and Surface Oncology and receives royalties from Up‐To‐Date. Yue Ren, Svitlana Tyekucheva, Jon E. Arnason, Adam M. Boruchov, Caron A. Jacobson, and David C. Fisher declare no relevant disclosures.

References:

• Burger JA. Treatment of chronic lymphocytic leukemia. N Engl J Med. 2020;383(5):460‐473.
• O'Brien S, Furman RR, Coutre S, et al. Single‐agent ibrutinib in treatment‐naïve and relapsed/refractory chronic lymphocytic leukemia: a 5‐year experience. Blood. 2018;131(17):1910‐1919.
• Munir T, Brown JR, O'Brien S, et al. Final analysis from RESONATE: up to six years of follow‐up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma. Am J Hematol. 2019;94(12):1353‐1363.
• Burris HA, Flinn IW, Patel MR, et al. Umbralisib, a novel PI3Kδ and casein kinase‐1ε inhibitor, in relapsed or refractory chronic lymphocytic leukaemia and lymphoma: an open‐label, phase 1, dose‐escalation, first‐in‐human study. Lancet Oncol. 2018;19(4):486‐496.
• Maharaj K, Powers JJ, Achille A, et al. The dual PI3Kδ/CK1ε inhibitor umbralisib exhibits unique immunomodulatory effects on CLL T cells. Blood Adv. 2020;4(13):3072‐3084.